Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01460901 · ClinicalTrials.gov registry record · Phase 1
Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma
A Phase 1 study, sponsored by Children's Mercy Hospital Kansas City.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT01460901 is a Phase 1 study that has completed, run by Children's Mercy Hospital Kansas City. The registered enrollment target is 5 participants.
The verdict
NCT01460901, a Phase 1 study, has completed, sponsored by Children's Mercy Hospital Kansas City.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a single-center, investigator-initiated, single-arm, pilot study of post-allogeneic transplant, adoptive immunotherapy for the treatment of patients with relapsed/refractory neuroblastoma expressing the mesenchymal tumor marker GD2. Three patients will be treated. The study will focus on the safety and efficacy of allogeneic, donor derived viral specific cytotoxic T-lymphocytes, retrovirally transduced to express a chimeric antigen receptor specific for disialoganglioside, GD2, expressed on neuroblastoma.
Interventions
- BIOLOGICAL GD2 CAR modified Tri-virus specific cytotoxic t-cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2012-10 |
| Est. Completion | 2015-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01460901
The ClinicalTrials.gov registry entry for NCT01460901 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Mercy Hospital Kansas City, which has 184 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GD2 CAR modified Tri-virus specific cytotoxic t-cells is the first listed.
NCT01460901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01460901 about?
NCT01460901 is a clinical study titled "Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma". This is a single-center, investigator-initiated, single-arm, pilot study of post-allogeneic transplant, adoptive immunotherapy for the treatment of patients with relapsed/refractory neuroblastoma expressing the mesenchymal tumor marker GD2. Three patients will be treated. The study will focus on the...
What is the current status of trial NCT01460901?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2012-10. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01460901?
The interventions under investigation include: GD2 CAR modified Tri-virus specific cytotoxic t-cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT01460901?
This trial is sponsored by Children's Mercy Hospital Kansas City, which has 184 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.